MI-3454,2134169-43-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MI-3454

CAS No. : 2134169-43-8

MCE 国际站：MI-3454

产品活性：MI-3454 是一种具有口服活性，高效和选择性的 Menin-MLL1 相互作用抑制剂，IC₅₀ 为 0.51 nM。MI-3454 通过下调涉及白血病发生的关键基因，在 MLL1 重排或 NPM1 突变的白血病小鼠模型中抑制细胞增殖，诱导分化并完全缓解或消退白血病。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vitro: MI-3454 (0.001-10 μM; 7 days) strongly reduces murine bone marrow cells transformed with MLL-AF9 or Hoxa9/Meis1 proliferation.
?MI-3454 (50 nM; 6 days) leads to downregulated expression of HOXA9 and MEIS1 in Human leukemic cell lines MV-4-11 cells or MOLM13.
?MI-3454 markedly reduces the viability of leukemic cells harboring various MLL fusion proteins (MLL-AF9, MLL-AF4, MLL-ENL), with GI₅₀ values ranging from 7 to 27 nM. MI-3454 blocks the interaction of menin with an MLL1_4–43 fragment encompassing the entire menin binding motif.
?MI-3454 does not potently inhibit cytochromes P450 (<50% inhibition at 10 μM).

In Vivo: MI-3454 induces complete remission or regression of leukemia in mouse models of mixed lineage leukemia 1 (MLL1)-rearranged or nucleophosmin 1 (NPM1)-mutated leukemia.
?MI-3454 (p.o.; 120 mg/kg; one or twice daily for 7 consecutive days) sufficiently blocks leukemia progression by a once-daily treatment.
?MI-3454 (p.o.; 100 mg/kg; b.i.d.; for 19 consecutive days) effectively blocks leukemia progression during the treatment period and markedly prolongs survival of MOLM13 xenotransplantation model mice. MI-3454 induces complete remission or blocks leukemia progression in patient-derived xenograft (PDX) models of MLL leukemia.
?MI-3454 (100 mg/kg of PO or 15 mg/kg of IV) has a T_1/2 of 3.2 hours, a C_max of 4698 mg/mL for PO.
?MI-3454 exhibits favorable stability in murine and human liver microsomes (t_1/2=20.4 minutes and 37.1 minutes, respectively).
?MI-3454 demonstrates lower levels in brain and cerebrospinal fluid, suggesting limited ability to cross the blood-brain barrier.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Reprogramming Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Protein-protein Interaction Inhibitor Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  (+)-JQ-1  |  Curcumin  |  A-485  |  C646  |  Revumenib  |  BRM/BRG1 ATP Inhibitor-1  |  BI 2536  |  dBET6  |  MZ 1  |  ARV-825  |  Inobrodib  |  Birabresib  |  666-15  |  SGC-CBP30  |  VTP50469  |  ACBI1  |  AU-15330  |  ARV-771  |  I-BET151  |  dBET1  |  dCBP-1  |  ABBV-744  |  Anacardic Acid  |  Molibresib  |  NSC 228155  |  KG-501  |  A-366  |  FHD-286  |  Mivebresib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds